Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Sells 9,039 Shares of Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 9,039 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $399,523.80. Following the completion of the sale, the general counsel now owns 195,037 shares in the company, valued at $8,620,635.40. This represents a 4.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Scholar Rock Stock Down 2.8 %

NASDAQ SRRK opened at $45.40 on Friday. The stock has a market capitalization of $4.25 billion, a P/E ratio of -19.32 and a beta of 0.52. Scholar Rock Holding Co. has a 52 week low of $6.76 and a 52 week high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The stock has a fifty day moving average of $40.69 and a 200-day moving average of $23.90.

Analyst Ratings Changes

A number of research firms have commented on SRRK. Wedbush restated an “outperform” rating and issued a $47.00 price target on shares of Scholar Rock in a research report on Thursday, January 9th. Truist Financial increased their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. JPMorgan Chase & Co. lifted their price objective on Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, October 14th. HC Wainwright boosted their price objective on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Finally, BMO Capital Markets raised their target price on Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, October 11th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $40.43.

Institutional Trading of Scholar Rock

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after purchasing an additional 514 shares during the period. GAMMA Investing LLC raised its stake in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares during the last quarter. Quarry LP lifted its holdings in Scholar Rock by 3,443.3% in the third quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after buying an additional 4,373 shares during the period. Nisa Investment Advisors LLC boosted its stake in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after acquiring an additional 1,031 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in Scholar Rock during the 2nd quarter worth $100,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.